PP
WINT

Paloma Partners’s Windtree Therapeutics WINT Stock Holding History

Paloma Partners’s Portfolio WINT Stock Details WINT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Hold
0
– -$95K – 2393
2020
Q4 		– Sell
-1
Closed -$277K – 1518
2020
Q3 		$204K Buy
+1
New +$336K 0.01% 1746

Other funds holding WINT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KC
Kepos Capital New York $73.4M AUM 4.78% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
PAM
PVG Asset Management Golden, Colorado $173M AUM 64.51% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Paloma Partners's WINT Position: Q1 2021 in Review

Paloma Partners held its Windtree Therapeutics (WINT) position steady in Q1 2021 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #2393.

Paloma Partners first reported a position in WINT in Q3 2020 and has held it in 1 quarter since. The position peaked at $204K in Q3 2020. 9 funds tracked by Wall St. Rank hold WINT as of Q1 2021.

  • Paloma Partners held 0 shares of Windtree Therapeutics worth $0 as of Q1 2021.
  • Paloma Partners left its Windtree Therapeutics share count unchanged in Q1 2021.
  • Windtree Therapeutics made up ﹤0.01% of Paloma Partners's portfolio in Q1 2021, its #2393 holding.
  • Paloma Partners first reported a position in Windtree Therapeutics in Q3 2020 and has held it in 1 quarter since.
  • Paloma Partners's Windtree Therapeutics position peaked at $204K in Q3 2020.
  • 9 funds tracked by Wall St. Rank held Windtree Therapeutics as of Q1 2021.

Based on Paloma Partners's 13F filing for Q1 2021, filed 17 May 2021.